LL-37 has no single legal status. It depends on the product and how it is supplied.
No FDA-approved U.S. LL-37 drug found; FDA plans an advisory-committee discussion before the end of February 2027. A research use only label does not make a product approved for people.
Pharmacy mixing (compounding): FDA had placed it in Category 2 for possible safety risks, and the request was then withdrawn (FDA page dated April 22, 2026).
Sports: we have no current sports-rule review for it yet.
Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
This is not legal advice.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
The record found no FDA-approved product. A label that says research use only does not make a product approved for people.
What the record says: No FDA-approved U.S. LL-37 drug found; FDA plans an advisory-committee discussion before the end of February 2027
Is it on FDA's compounding safety list?
Nomination withdrawn
Listed as cathelicidin LL-37.
FDA had placed it in Category 2 for possible safety risks. The person who asked FDA to allow it in compounding then withdrew the request. FDA still lists its safety concerns and has not made a final decision. A withdrawn request is neither a ban nor an approval.